Antibody–drug conjugates (ADCs) represent a groundbreaking class of targeted cancer therapies that have revolutionized the landscape of cancer treatment. At the heart of ADCs lies a sophisticated and innovative approach to delivering potent cytotoxic agents directly to cancer cells while sparing healthy tissues. The success of ADCs is intricately tied to the careful selection and design of the payload, which is the therapeutic component responsible for inducing cell death within the targeted cancer cells.
In the realm of ADCs, the payload serves as the "warhead," delivering a highly potent cytotoxic drug with precision and specificity. This targeted payload delivery is achieved through the combination of a monoclonal antibody, which acts as a homing mechanism by recognizing and binding to specific antigens on the surface of cancer cells, and a linker system that connects the antibody to the cytotoxic payload. The payload is strategically chosen to maximize efficacy against the particular cancer type while minimizing off-target effects, thereby enhancing the therapeutic window of the ADC.
Detecting the conjugation of a payload to an antibody in the context of Antibody–Drug Conjugates (ADCs) is crucial for ensuring the success and specificity of the therapeutic approach. We have developed several anti-payload monoclonal antibody for payload detection.
Recombinant DT3C (Diphtheria toxin & spg 3C domain) for Antibody Internalization Assay